IQVIA Holdings Inc.
IQV - NYSE - $178.71 ▲ +%0.04
-
Earnings Tue 28 Jul

IQVIA opens the
books on Tuesday evening.

5 analysts' median target is $223[FMP target], stock is $179, +24.5% upside potential. After Q1 +2.5% EPS beat[FMP earnings], the stock moved +0.0%.

↓ summary below
Quick Take - in 40 seconds
A-
BUY Council 3/6 - Moonshot 40

A- = MoonshotScore 40[9-pillar formula] + Council 3/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].

Q4 consensus: revenue $4.3B[FMP est], EPS $3.03[FMP est]. 8 consecutive quarters of beat[FMP earnings].

Detailed analysis below ↓
$3.03 EPS Estimate Last year $3.42 - +8% YoY YoY
8 Beat Streak Expectations beaten consecutively for the last 8 quarters

Q1 EPS +2.5% beat[FMP] but the stock +0.0% D+1[FMP D+1]. Michael Fedock promised $0 CapEx + a sequential decline in Q4 during the Q1 earnings call[Michael Fedock capex transcript].

Watchlist

5 metrics stand out this quarter.

$552 million Expectation / Guide

Fy26 Eps Guidance Increase

fy26_eps_guidance_increase

IQVIA Holdings Inc. reaffirmed its full year 2026 guidance for revenue and adjusted EBITDA and raised the guidance for adjusted diluted earnings per share.

"We repurchased $552 million of our shares in the first quarter, and we reaffirmed our full year 2026 guidance for revenue and adjusted EBITDA and raised the guidance for adjusted diluted earnings per share."

- Michael Fedock, Executive Vice President and Chief Financial Officer - Q1 FY26 Earnings Call - May 5, 2026
192 Investor Focus

Ai Agent Deployment

ai_agent_deployment

IQVIA Holdings Inc. has deployed 192 agents in the field covering 64 use cases across Commercial and R&D Solutions, with 19 of the top 20 pharma companies trusting its AI capabilities.

"To date, we have 192 agents deployed in the field covering 64 use cases across both our Commercial Solutions and R&D Solutions businesses. Nineteen of the top twenty pharma companies are already using IQVIA Holdings Inc. agents in some of their workflows, underscoring broad industry trust in our AI capabilities."

- Ari Bousbib, Chairman and Chief Executive Officer - Q1 FY26 Earnings Call - May 5, 2026
$34.2 billion Investor Focus

Record Backlog

record_backlog

IQVIA Holdings Inc.’s backlog reached a new record of $34.2 billion, with $8.9 billion expected to convert to revenue in the next twelve months.

"Our backlog reached a new record of $34.2 billion at the end of the quarter. Noteworthy is the amount of dollars from our backlog that will convert to revenue in the next twelve months. We have $8.9 billion out of our backlog, representing nearly 8% growth year over year versus the recast numbers last year."

- Ari Bousbib, Chairman and Chief Executive Officer - Q1 FY26 Earnings Call - May 5, 2026
doubled Investor Focus

Commercial Solutions Growth

commercial_solutions_growth

IQVIA Holdings Inc. saw its organic revenue growth rate in Commercial Solutions double.

"In fact, year over year, our organic revenue growth rate in Commercial Solutions doubled, and our organic revenue growth rate in R&D Solutions tripled."

- Ari Bousbib, Chairman and Chief Executive Officer - Q1 FY26 Earnings Call - May 5, 2026
doubled Investor Focus

Rd Solutions Growth

rd_solutions_growth

IQVIA Holdings Inc. saw its organic revenue growth rate in R&D Solutions triple.

"In fact, year over year, our organic revenue growth rate in Commercial Solutions doubled, and our organic revenue growth rate in R&D Solutions tripled."

- Ari Bousbib, Chairman and Chief Executive Officer - Q1 FY26 Earnings Call - May 5, 2026

Stock Expert AI - Methodology

Do our 9 pillars, 7 perspectives, and Munger lens point in the same direction?

MoonshotScore 40 / 100

9-pillar methodology. Price Momentum and News Sentiment strong. Revenue Growth weak.

How is it calculated? ->
Revenue Growth2.0Q1 vs Q2: moderate growth (+3.3%)
Gross Margin3.0Q1: average margin (32.6%)
Operating Leverage1.0op margin average (12.4%)
Cash Runway3.0FCF very strong ($0.6B, 618000000.0x CapEx)
R&D Intensity3.0low R&D investment (0.0%, weak innovation)
Price Momentum7.0RSI 60.4 positive momentum, 50d above
News Sentiment9.0strong buy consensus (91%)
Council Score 3 / 6 Bullish

6 investor frameworks. 3 bullish (Ray Dalio, Ken Griffin, Buffett), 0 bearish (none), 3 neutral (Jim Simons, Klarman, Munger).

How is it calculated? ->
Ray Dalio macro - target upside +24.5%
Ken Griffin flow - 50d MA above
Jim Simons quant - RSI 60
Klarman value - target upside +24.5%
Buffett quality - ROE score 5/5
Munger valuation - target upside +24.5%
Munger's Mindset character & balance sheet lens
Fairly Valued

Quality business, trading at fair value.

How is it calculated? ->
Financial HealthStrong
Margin of SafetyModerate
Interest CoverageAdequate
ROIC vs WACCHealthy
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
60.4 RSI 60.4 positive momentum, 50d above
MACD
+5.20 price above 50d - support positive
50d MA
$170 stock 5.2% above - short-term support
200d MA
$197 stock 9.3% below - long-term pressure
Volume (10d)
-46% decrease - low participation
Resistance
$223
Analyst median target - upgrade trigger if broken
Current
$179
Pre-earnings position
Support
$167
Invalidation - close below this is a technical breakdown
Pattern
Range
$167-$223 band - earnings breakout/breakdown trigger

Past Performance

IQVIA beat expectations in the last 8 quarters.

BEAT
Q2 FY25
$2.81 vs $2.77 est - +3.7%
BEAT
Q3 FY25
$3.00 vs $2.98 est - -0.1%
BEAT
Q4 FY25
$3.42 vs $3.40 est - +3.6%
BEAT
Q1 FY26
$2.90 vs $2.83 est - +0.0%

Q1 (May 5, 2026): EPS $2.90 vs $2.83 est[FMP], +2.5% beat. D+1 movement: +0.0%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.

Three scenarios: what could happen?

EPS < $2.94 (no guidance)

Q1: EPS $2.90 vs $2.83 beat[FMP], stock +0.0% D+1[FMP].

Backlog concentration

No RPO/backlog concentration disclosed in Q1 earnings call.

CapEx shock

Q1 CapEx $0[FMP cashflow]. Q1 op margin 12.4%[FMP op margin] - this level in Q4 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q4 EPS > $3.03 + CapEx discipline
Threshold: EPS > $3.03[FMP est].
Target: Break above median target $223[FMP target]; high target $250[FMP] upper bound.
Scenario B - In-Line
EPS approx $3.03 + CapEx < $0
Threshold: EPS approx $3.03[FMP est], Q4 CapEx < $0[FMP].
Target: Consolidation in the band between current $179[FMP] and median $223[FMP].
Scenario C - Miss
EPS < $2.94 or CapEx >= $0
Threshold: EPS < $2.94[FMP estx0.97].
Target: Current $179 below SMA200 $197[FMP], if rejection continues, $167[derived] support activates.
Sizing
Earnings volatility -> max portfolio 1-2%. Waiting for earnings is not a gamble, it's a position entrustment.
Timing
IV crush within 24 hours post-earnings. Waiting for premium decay makes options preferable to spot.
Staging
Don't go all-in at once, divide into 3: initial reaction, 24 hours later, after Friday's close.

Market Outlook

What do 5 analysts say?

Wall Street Consensus
$223
12-month median target price (+24.5% upside potential)
21
BUY
2
HOLD
0
SELL
Risk Management
$167
Invalidation level - critical support threshold
$170 - 50-day MA (above, +5.2%)
$197 - 200-day MA (below, -9.3%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - IQV Q4 FY26
A-

You read it in 5 minutes. When the numbers come out on Tuesday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Tuesday evening. The framework is ready on this page: Q4 EPS threshold $3.03[FMP], CapEx threshold "below $0"[Michael Fedock]. Two anchors, three scenarios.

Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore 9-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Try Pro free for 14 days IQV dossier ->

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Jul 28, 2026EARNINGSQ4 FY26 results (after market close) + earnings call
Jul 29, 2026PRICEFirst trading day after earnings - 200dMA test + IV crush
Sep 11, 2026FILING10-Q deadline - segment breakdown + RPO detail (SEC rule: quarter-end + 45 days)
~Oct 28, 2026EARNINGSQ1 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the IQV earnings preview cover?

This IQV (IQV) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in IQV earnings?

Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.